Wuhan Keqian Biology Co.,Ltd (SHA:688526)
12.36
-0.09 (-0.72%)
Sep 23, 2026, 3:00 PM CST
SHA:688526 Revenue
Wuhan Keqian Biology Co.,Ltd had revenue of 146.29M CNY in the quarter ending June 30, 2026, a decrease of -39.57%. This brings the company's revenue in the last twelve months to 836.28M, down -18.71% year-over-year. In the year 2025, Wuhan Keqian Biology Co.,Ltd had annual revenue of 949.74M with 0.83% growth.
Revenue (ttm)
836.28M
Revenue Growth
-18.71%
P/S Ratio
6.86
Revenue / Employee
894.42K
Employees
935
Market Cap
5.73B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 949.74M | 7.82M | 0.83% |
| Dec 31, 2024 | 941.92M | -122.15M | -11.48% |
| Dec 31, 2023 | 1.06B | 62.81M | 6.27% |
| Dec 31, 2022 | 1.00B | -101.75M | -9.22% |
| Dec 31, 2021 | 1.10B | 259.79M | 30.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 15.93B |
| Youcare Pharmaceutical Group | 2.46B |
| Chengdu Kanghua Biological Products | 1.22B |
| ChemPartner PharmaTech | 1.16B |
| Boji Medical Technology | 961.34M |
| R&G PharmaStudies | 939.31M |
| Zhejiang Ausun Pharmaceutical | 778.50M |
| Jiangsu Aidea Pharmaceutical Group | 722.54M |